<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03104855</url>
  </required_header>
  <id_info>
    <org_study_id>50852</org_study_id>
    <secondary_id>R01DK099199</secondary_id>
    <secondary_id>P30DK089507</secondary_id>
    <nct_id>NCT03104855</nct_id>
  </id_info>
  <brief_title>Clearance of 25-hydroxyvitamin D in Cystic Fibrosis</brief_title>
  <acronym>CF</acronym>
  <official_title>Clearance of 25-hydroxyvitamin D in Cystic Fibrosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Washington</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Washington</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goal of this study is to define 25(OH)D3 catabolism in CF patients using gold standard
      pharmacokinetics studies. Specifically, the investigators will evaluate the metabolic
      clearance of 25(OH)D3 among participants with CF and matched control subjects. The goal of
      this work is to provide the first comprehensive characterization of vitamin D metabolism in
      CF patients and promote novel hypotheses for subsequent studies.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 3, 2017</start_date>
  <completion_date type="Anticipated">December 2019</completion_date>
  <primary_completion_date type="Anticipated">December 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Metabolic clearance of D6-25(OH)D3</measure>
    <time_frame>8 weeks</time_frame>
    <description>Metabolic clearance is calculated as the administered dose of 25(OH)D3 divided by the area under the plasma concentration-time curve (AUC). AUC is calculated using the linear trapezoidal method.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>AUC of D6-25(OH)D3</measure>
    <time_frame>8 weeks</time_frame>
    <description>AUC is calculated using the linear trapezoidal method.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Terminal half-life of D6-25(OH)D3</measure>
    <time_frame>8 weeks</time_frame>
    <description>Terminal half-life is equal to ln2/k, where k is the slope of the terminal regression line estimated using ≥3 plasma concentrations.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Volume of distribution of D6-25(OH)D3</measure>
    <time_frame>8 weeks</time_frame>
    <description>Volume of distribution in the central compartment is calculated as dose/C0, where dose is the administered dose of 25(OH)D3 and C0 is the initial (estimated) concentration of drug in plasma.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Metabolic formation clearance of D6-25(OH)D3 metabolites</measure>
    <time_frame>8 weeks</time_frame>
    <description>Metabolic formation clearance is calculated as the daughter metabolite plasma AUC divided by the AUC of D6-25(OH)D3 (metabolite/parent AUC ratio). AUC is calculated using the linear trapezoidal method.</description>
  </other_outcome>
  <other_outcome>
    <measure>serum concentration of calcium</measure>
    <time_frame>7 days</time_frame>
    <description>Change in the serum concentration of calcium from baseline to 7 days after 25(OH)D3</description>
  </other_outcome>
  <other_outcome>
    <measure>serum concentration of creatinine</measure>
    <time_frame>7 days</time_frame>
    <description>Change in the serum concentration of creatinine from baseline to 7 days after 25(OH)D3</description>
  </other_outcome>
  <other_outcome>
    <measure>serum concentration of AST</measure>
    <time_frame>7 days</time_frame>
    <description>Change in the serum concentration of AST from baseline to 7 days after 25(OH)D3</description>
  </other_outcome>
  <other_outcome>
    <measure>serum concentration of ALT</measure>
    <time_frame>7 days</time_frame>
    <description>Change in the serum concentration of ALT from baseline to 7 days after 25(OH)D3</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Cystic Fibrosis</condition>
  <arm_group>
    <arm_group_label>Single pharmacokinetics arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>d6-25-hydroxyvitamin D3</intervention_name>
    <description>intravenous administration of stable isotope-labeled D6-25(OH)D3</description>
    <arm_group_label>Single pharmacokinetics arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age ≥ 18 years

          -  Serum total 25(OH)D 10-50 ng/mL

          -  Diagnosis of cystic fibrosis in accordance with CF Foundation Guidelines; OR, normal
             CONTROL

        Exclusion Criteria:

          -  Primary hyperparathyroidism

          -  Gastric bypass

          -  Tuberculosis or sarcoidosis

          -  Current pregnancy

          -  Child-Pugh Class B or C cirrhosis (i.e. cirrhosis with ascites, hepatic
             encephalopathy, bilirubin &gt;=2 mg/dL, serum albumin &lt;=3.5 g/dL, or PT &gt;= 4 seconds)

          -  History of kidney transplantation or end stage renal disease treated with dialysis

          -  Use of vitamin D3 or vitamin D2 supplements exceeding a mean daily dose of 400 IU,
             within 3 months (wash-out allowed)

          -  Use of 1,25(OH)2D3 or an analogue, calcimimetics, or medications known to induce
             CYP24A1 within 4 weeks (wash-out allowed)

          -  Serum calcium &gt; 10.1 mg/dL

          -  Hemoglobin &lt; 9 g/dL
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ian de Boer, MD, MS</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Washington</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Laura Curtin</last_name>
    <phone>206 221-3938</phone>
    <email>LCurtin@Nephrology.washington.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ashveena Dighe</last_name>
    <phone>206-744-4029</phone>
    <email>ashveena@uw.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Washington</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laura Curtin</last_name>
      <phone>206-221-3938</phone>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 17, 2017</study_first_submitted>
  <study_first_submitted_qc>April 6, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">April 7, 2017</study_first_posted>
  <last_update_submitted>March 22, 2018</last_update_submitted>
  <last_update_submitted_qc>March 22, 2018</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 26, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Washington</investigator_affiliation>
    <investigator_full_name>Ian deBoer</investigator_full_name>
    <investigator_title>Associate Professor, Medicine/Nephrology</investigator_title>
  </responsible_party>
  <keyword>cystic fibrosis</keyword>
  <keyword>vitamin d catabolism</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fibrosis</mesh_term>
    <mesh_term>Cystic Fibrosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hydroxycholecalciferols</mesh_term>
    <mesh_term>Calcifediol</mesh_term>
    <mesh_term>Vitamin D</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

